Jing Han1, Lin Ma. 1. Department of Neuroradiology, Huanhu Hospital, Tianjin 300060, China.
Abstract
PURPOSE: To study the features of proton magnetic resonance spectroscopy ((1)H-MRS) on amyotrophic lateral sclerosis (ALS) and its relation with clinical scale. MATERIALS AND METHODS: Fifteen patients with definite or probable ALS and 15 age- and gender-matched normal controls were enrolled. (1)H-MRS was performed on a 3.0 Tesla GE imaging system (GE Healthcare, Milwaukee, WI). TE-averaged Point Resolved Selective Spectroscopy was used. N-acetylaspartate (NAA), creatine (Cr), Glu, and Glx (glutamate + glutamine) values of the motor cortex and posterior limb of internal capsule were acquired. The t-test was used to compare differences between groups, and the correlations between the above values and clinical scale were analyzed. RESULTS: The motor area and posterior limb of the internal capsule of ALS patients had lower NAA/Cr (1.91 +/- 0.34, 1.53 +/- 0.17) compared with normal subjects (2.23 +/- 0.33, 1.66 +/- 0.07), and the differences between groups were statistically significant (P < 0.01, 0.01). ALS patients had higher Glu/Cr (0.34 +/- 0.05, 0.29 +/- 0.06) and Glx/Cr (0.40 +/- 0.04, 0.33 +/- 0.06) compared with normal subjects (0.30 +/- 0.03, 0.25 +/- 0.04) and (0.32 +/- 0.05, 0.26 +/- 0.03), and the differences between groups were statistically significant (P < 0.01, 0.01). The Norris scale was negatively correlated with Glx/Cr of primary motor cortex by lineal correlation analysis (r = -0.75), and this correlation had statistical significance (F = 16.60; P = 0.001). CONCLUSION: Neuronal loss and Glu+Gln increase can be detected by using proton MRS in ALS patients. (1)H-MRS is an useful tool in reflecting the characteristic changes of metabolite in ALS.
PURPOSE: To study the features of proton magnetic resonance spectroscopy ((1)H-MRS) on amyotrophic lateral sclerosis (ALS) and its relation with clinical scale. MATERIALS AND METHODS: Fifteen patients with definite or probable ALS and 15 age- and gender-matched normal controls were enrolled. (1)H-MRS was performed on a 3.0 Tesla GE imaging system (GE Healthcare, Milwaukee, WI). TE-averaged Point Resolved Selective Spectroscopy was used. N-acetylaspartate (NAA), creatine (Cr), Glu, and Glx (glutamate + glutamine) values of the motor cortex and posterior limb of internal capsule were acquired. The t-test was used to compare differences between groups, and the correlations between the above values and clinical scale were analyzed. RESULTS: The motor area and posterior limb of the internal capsule of ALSpatients had lower NAA/Cr (1.91 +/- 0.34, 1.53 +/- 0.17) compared with normal subjects (2.23 +/- 0.33, 1.66 +/- 0.07), and the differences between groups were statistically significant (P < 0.01, 0.01). ALSpatients had higher Glu/Cr (0.34 +/- 0.05, 0.29 +/- 0.06) and Glx/Cr (0.40 +/- 0.04, 0.33 +/- 0.06) compared with normal subjects (0.30 +/- 0.03, 0.25 +/- 0.04) and (0.32 +/- 0.05, 0.26 +/- 0.03), and the differences between groups were statistically significant (P < 0.01, 0.01). The Norris scale was negatively correlated with Glx/Cr of primary motor cortex by lineal correlation analysis (r = -0.75), and this correlation had statistical significance (F = 16.60; P = 0.001). CONCLUSION:Neuronal loss and Glu+Gln increase can be detected by using proton MRS in ALSpatients. (1)H-MRS is an useful tool in reflecting the characteristic changes of metabolite in ALS.
Authors: Isabelle M Rosso; David J Crowley; Marisa M Silveri; Scott L Rauch; J Eric Jensen Journal: Neuropsychopharmacology Date: 2017-02-13 Impact factor: 7.853
Authors: John W Totenhagen; Eriko S Yoshimaru; Robert P Erickson; Theodore P Trouard Journal: J Magn Reson Imaging Date: 2012-11-16 Impact factor: 4.813
Authors: Stefan Sivák; Michal Bittšanský; Egon Kurča; Monika Turčanová-Koprušáková; Milan Grofik; Vladimír Nosál'; Hubert Poláček; Dušan Dobrota Journal: Neuroradiology Date: 2010-04-06 Impact factor: 2.804
Authors: Ian Cheong; Małgorzata Marjańska; Dinesh K Deelchand; Lynn E Eberly; David Walk; Gülin Öz Journal: Neurochem Res Date: 2017-04-03 Impact factor: 3.996